VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for anxiety, depression, and other central nervous system disorders. Headquartered in South San Francisco, California, VistaGen is advancing its proprietary drug candidates, including AV-101, which aim to address significant unmet medical needs in the mental health space. The company's commitment to addressing CNS disorders positions it as a promising player in the evolving landscape of mental health therapeutics, with a robust pipeline that leverages its expertise in neuropharmacology.